Trials / Completed
CompletedNCT02101580
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Polaris Group · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-PEG 20 |
Timeline
- Start date
- 2014-11-17
- Primary completion
- 2017-05-05
- Completion
- 2017-10-06
- First posted
- 2014-04-02
- Last updated
- 2020-10-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02101580. Inclusion in this directory is not an endorsement.